



A MedTech Europe event

The MedTech Forum

bringing HealthTech stakeholders together

Moving from a pharma to a cross sectorial partnership

Pierre Meulien, IMI Executive Director

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

IMI 2 Fostering Public/Private Collaboration and Partnership

EU funding goes to:

Universities
SMEs
Mid-sized companies
Patient groups
etc...



€1.638 bn



€1.425 bn

Other
€213 m

IMI 2 total budget
€3.276 billion

EFPIA companies

receive no funding
contribute to projects 'in kind'

Associated Partners e.g. charities, non-EFPIA companies

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

Current involvement of other industry sectors in IMI2

3 channels

- IMI2 Associated Partners
 - ✓ e.g. Software AG, DataPharm, Accelerate Diagnostics, Bd Switzerland
- IMI2 beneficiaries not receiving funding
 - e.g. Echosens in the [Litmus project](#)
- EFPIA Partners in Research <https://www.efpia.eu/about-us/membership>
 - ✓ Participation in ~ 30 projects
 - ✓ Total contribution ~ EUR 53,2M

Figures as of end 2020

IMI2 Associated Partners (as of Spring 2021)

Accelerate Diagnostics
Autism Speaks
Autistica
BD Switzerland Sarl
Bill and Melinda Gates Foundation (BMGF)
Bio-rad Laboratories
Cepheid Europe
CHDI Foundation
Children's Tumor Foundation
Coalition for Epidemic Preparedness (CEPI)
Datapharm
Diamond Light Source
Deutsches Zentrum für Infektionsforschung (DZIF)
European Hematology Association (EHA)
Global Health Drug Discovery Institute (GHDDI)
Helmsley Charitable Trust (HCT)
International Diabetes Foundation (IDF)
Invicro
Ion Beam Applications (IBA)

JDRF
Klinikum der Universität München
KTH Royal Institute of Technology

Link 2 Trials
McGill University
Medicines for Europe
Medicines for Malaria Venture (MMV)
Obesity Action Coalition
Ontario Institute for Cancer Research
Parkinson's UK
Simon Foundation Autism Research (SFARI)
Software AG
Springworks Therapeutics
T1D Exchange
TB Alliance
Trial Nation
University of Dundee
Varian Medical Systems Particle Therapy
Wellcome Trust

Total Number of Associated Partners: 38
Total signed agreements and full proposals: EUR 201,083,827

EFPIA Partners in Research

APEIRON BIOLOGICS

Benevolent



Cognizant

COVANCE
SOLUTIONS MADE REAL

ELLEGAARD
GÖTTINGEN MINIPIGS



FUJIFILM
Value from Innovation

GATES VENTURES



genuity
science

ICON
A Symbol of Excellence

illumina



INSTITUT MERIEUX

IQVIA



Life
Molecular Imaging

Lonza

McKinsey&Company

medidata

Medtronic

nanoString

NORDIC BIOSCIENCE



PsychoGenics

sas

Science 37

SomaLogic

STEMCELL
TECHNOLOGIES

SVAR



Vironova



zoetis

AMYPAD

Amyloid imaging to prevent Alzheimer's disease

- 2 imaging companies:
GE Healthcare and **Life Molecular Imaging**
- collaborating with Janssen Pharmaceuticals
- Study of value of PET amyloid in for diagnosis and clinical trials of patients with Alzheimer's disease

PET scans that show brain changes caused by Alzheimer's give doctors confidence in diagnosis

Being able to visualise the pathology linked to the disease is a big benefit for diagnosis and patient management.



Brain imaging is used in the diagnosis of Alzheimer's. Amyloid PET scans are a newer technology and researchers from the AMYPAD project are trying to understand how they influence diagnosis. Image by CSIRO CC 3.0.

Value-DX

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

- 1st IMI project initiated by 6 in vitro Dx companies
- Objectives:
 - ✓ Design a health-economic framework to assess & demonstrate the value of diagnostics to optimize antibiotic use and reduce AMR
 - ✓ Establish a sustainable European Standardised Care Network adequately trained and resourced to conduct clinical trials
- Major interest of the Dx sector:
 - ✓ Explore and resolve the psychological, ethical and social barriers which prevent a more widespread adoption of diagnostics delivering healthcare to the population
 - ✓ Federate IVD players around health economics initiatives and new HTA models

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

2021 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

Proton vs. Photon Therapy

Focussed on oesophageal cancer

- 1st IMI topic initiated by COCIR members
- Main objective: To examine the value of proton therapy as a treatment modality through a clinical study in oesophageal cancer
- Led by Ion Beam Applications SA & Varian Medical Systems Particle Therapy GmbH
- Total budget: EUR 3M

Under signature

IMI, an ecosystem for innovative collaborations

Neutral platform

Open collaboration

Shared challenges in areas of unmet medical needs

Transformative solutions to reduce late stage attrition, speed patient access and improve health

Regulators

HTA bodies

Payers

Healthcare practitioners

Academia

Charities

SMEs

Pharma companies

Diagnostic companies

Other sectors (e.g imaging, nutrition...)

Public health bodies

Patients



2021 © The MedTech Forum. All rights reserved. Reproduction in whole or in part is prohibited

2021 © The MedTech Forum. All rights reserved. Reproduction in whole or in part is prohibited